|Bid||2.7600 x 21500|
|Ask||2.8000 x 29200|
|Day's range||2.7000 - 2.8350|
|52-week range||2.3500 - 5.1400|
|Beta (5Y monthly)||1.67|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
AKBA earnings call for the period ending September 30, 2021.
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -6.25% and -2.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.